Research
expert reaction to abstract about Daraxonrasib plus GnP for metastatic pancreatic adenocarcinoma
The Brief
- An abstract presented at EORTC-NCI-AACR 2026 reports on daraxonrasib plus GnP for metastatic pancreatic adenocarcinoma.
- Shivan Sivakumar, Professor of Translational Oncology at the University of Birmingham, described the results as very encouraging.
Why it matters
The source covers early expert reaction to a treatment combination tested in metastatic pancreatic adenocarcinoma, a disease where the expert called the results encouraging. Only the abstract and a brief expert reaction are available, so the full data are not yet known.
Who’s affected
- oncologists and pancreatic cancer researchers
- patients with metastatic pancreatic adenocarcinoma and their clinicians
- #pancreatic cancer
- #metastatic cancer
- #oncology
- #daraxonrasib
- #clinical research
Scientist reacts to abstract presented at EORTC-NCI-AACR 2026* about Daraxonrasib plus GnP for metastatic pancreatic adenocarcinoma. Prof Shivan Sivakumar, Professor of Translational Oncology, University of Birmingham, said: “These are very encouraging results in a disease where…